SciSparc Grants Global Rights For Pain Therapy To Polyrizon Ltd In Agreement Worth Up To $6M, $3M In Polyrizon Securities, As Well As Potential Milestone Fees Of ~$3M In Cash
Portfolio Pulse from Benzinga Newsdesk
SciSparc Ltd. has granted Polyrizon Ltd. global rights to its SCI-160 pain therapy program in a deal worth up to $6 million. SciSparc will receive $3 million in Polyrizon securities and potential milestone fees of $3 million in cash.
August 28, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc Ltd. has entered into an agreement with Polyrizon Ltd. to out-license its SCI-160 pain therapy program. The deal is valued at up to $6 million, with $3 million in Polyrizon securities and potential milestone fees of $3 million in cash.
The agreement with Polyrizon Ltd. provides SciSparc with a significant financial opportunity through securities and potential cash milestone fees. This could positively impact SciSparc's financial position and investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90